Nordic Pharmaceuticals Limited, a active public limited company, was established on 16 September 1997 in New Delhi, Delhi, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U24231DL1997PLC089698. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹2.50 M and a paid-up capital of ₹1.15 M.
It upholds a compliant status. Its leadership includes Kusum Poddar (Director), Banwari Lal Poddar (Director), Manoj Kumar Poddar (Director). Past directors included Santosh Poddar. It holds ₹4.70 M open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Nordeic House D 318, Avantika Sector I, Rohini, New Delhi, Delhi, 110085.
U24231DL1997PLC089698
089698
16 September 1997
₹2.50 M
₹1.15 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Nordic Pharmaceuticals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kusum Poddar | Director | 30 Mar 2015 | Current |
| Banwari Lal Poddar | Director | 16 Sep 1997 | Current |
| Manoj Kumar Poddar | Director | 16 Sep 1997 | Current |
| Manish Poddar | Director | 16 Sep 1997 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 11 Oct 2022 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Nordic Pharmaceuticals Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 50.65% increase. The company also saw a substantial improvement in profitability, with a 293.77% increase in profit. The company's net worth moved up by a moderate rise of 7.41%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2022, Nordic Pharmaceuticals had a promoter holding of 97.75% and a public holding of 2.25%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹4,699,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Jun 2014 | Bank Of India | ₹0.70 M | Open |
| 01 Feb 1999 | Bank Of India | ₹4.00 M | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Nordic Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Nordic Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nordic Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Nordic Pharmaceuticals Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
The activity Nordic Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was completed.
The activity A charge with Bank Of India of Rs. 4.00 M registered on 01 Feb 1999 with Charge ID 90035047 was modified on 08 Mar 2019. was completed.
Kusum Poddar was appointed as a Director was appointed as a Director on 30 Mar 2015 & has been associated with this company since 10 years 8 months . was recorded as a recent event.
Progress on A charge with Bank Of India amounted to Rs. 0.70 M with Charge ID 10510423 was registered on 26 Jun 2014. was documented.
Progress on A charge with Bank Of India amounted to Rs. 4.00 M with Charge ID 90035047 was registered on 01 Feb 1999. was documented.
Nordic Group and Primex team up to make sick people feel better. They make meds for hospitals and rare diseases. #PharmaPowerCouple #SavingLives #BossMoves.
/PRNewswire/ -- Cumberland Pharmaceuticals (NASDAQ: CPIX), a U.S. specialty pharmaceutical company has entered into an Agreement to acquire the exclusive U.S.....
The CIN of Nordic Pharmaceuticals Limited is U24231DL1997PLC089698.
Nordic Pharmaceuticals Limited is headquartered at Nordeic House D 318, Avantika Sector I, Rohini, New Delhi, Delhi, 110085.
Nordic Pharmaceuticals Limited was incorporated on 16 September 1997.
The current directors of Nordic Pharmaceuticals Limited are
The primary industry of Nordic Pharmaceuticals Limited is Trade.
Nordic Pharmaceuticals Limited is unlisted.
The authorized capital of Nordic Pharmaceuticals Limited is ₹2.50 M, and the paid-up capital is ₹1.15 M.
The compliance status of Nordic Pharmaceuticals Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX